Ataraxis Breast
Breast Cancer Prognosis & Treatment Response
CommercialClinically Available
Key Facts
Indication
Breast Cancer Prognosis & Treatment Response
Phase
Commercial
Status
Clinically Available
Company
About Ataraxis AI
Ataraxis AI is a clinical-stage AI company spun out of New York University in 2023, focused on developing and deploying AI-powered tools to improve cancer prognosis and treatment selection. The company has raised a $20.4 million Series A round and has launched its first product, Ataraxis Breast, a prognostic tool that delivers results within 24 hours using existing pathology slides. Backed by a world-class team and advisors like AI pioneer Yann LeCun, Ataraxis is collaborating with top international cancer centers to validate and implement its technology across multiple cancer types.
View full company profile